NANOBIOTIX SA - ADR

NBTXNASDAQ

🏆 #1971 by market capEarnings Sep 28US Equity

$39.44▲ $0.73 (+1.86%)

🌙 After hours$39.44▲ 0.00%Regular close · extended-hours price shown

1h—

24h▲ 1.9%

7d▲ 0.1%

14d▲ 6.8%

30d▲ 1.0%

1y▲ 409.6%

🏦Market Cap

$2.00B

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

57.1x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $39.31 – $40.21
52-Week Range: —
Volume: $2.25B
Avg Volume: $2.90B
Shares Outstanding: 50.6M
Next Earnings: Sep 19, 2026

Fundamentals Snapshot

Annual Revenue: $30M
Last Q Revenue: $3M
P/E Ratio: —
P/S Ratio: 57.1x
EPS (TTM): —
Dividend Yield: —

Why Investors Own NBTX

✓High-growth profile — revenue up +23.2% YoY with expanding US Equity exposure.
✓Healthy economics — 50% gross margin and 8% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$30M▲ +24.0% YoY

Gross Margin (TTM)

49.7%▲ +2.8% YoY

Operating Income (TTM)

$10M▲ +24.0% YoY

Free Cash Flow (TTM)

$2M▲ +24.0% YoY

About NANOBIOTIX SA - ADR

Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.

🦦